Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 85.9%

Neg 0% Neu 0% Pos 85.9%

Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $9 to $13.